Advanced Gastric Carcinoma - Pipeline Insight, 2021
This report can be delivered to the clients within 3-5 business days
DelveInsight’s, “Advanced Gastric Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Advanced Gastric Carcinoma: Overview
Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms. Treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.
'Advanced Gastric Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Gastric Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Gastric Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Gastric Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Advanced Gastric Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Gastric Carcinoma Emerging Drugs
Further product details are provided in the report.
Advanced Gastric Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Advanced Gastric Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Gastric Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Gastric Carcinoma drugs.
Advanced Gastric Carcinoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Advanced Gastric Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Advanced Gastric Carcinoma: Overview
Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms. Treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.
'Advanced Gastric Carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Gastric Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Gastric Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Gastric Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Gastric Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Gastric Carcinoma.
This segment of the Advanced Gastric Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Gastric Carcinoma Emerging Drugs
- Camrelizumab: Jiangsu Hengrui Medicine
- Pamiparib: BeiGene
Further product details are provided in the report.
Advanced Gastric Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Gastric Carcinoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Advanced Gastric Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Gastric Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Gastric Carcinoma drugs.
Advanced Gastric Carcinoma Report Insights
- Advanced Gastric Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Gastric Carcinoma drugs?
- How many Advanced Gastric Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Gastric Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Gastric Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Gastric Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Jiangsu Hengrui Medicine
- BeiGene
- CSPC ZhongQi Pharmaceutical Technology
- LintonPharm Co.,Ltd.
- Bristol-Myers Squibb
- Hanmi Pharmaceutical
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Idience Co., Ltd.
- Shanghai Henlius Biotech
- AstraZeneca
- Nanjing Legend Biotech Co.
- ALX Oncology Inc.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Genentech
- Innovent Biologics (Suzhou) Co. Ltd.
- Qilu Pharmaceutical Co., Ltd.
- NextCure, Inc.
- Chengdu Kanghong Biotech Co., Ltd.
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Janssen Pharmaceutical K.K.
- Shanghai Miracogen Inc.
- Ambrx, Inc.
- Imugene Limited
- Vedanta Biosciences, Inc.
- Celon Pharma SA
- Bicycle Tx Limited
- Seagen Inc.
- Camrelizumab
- Pamiparib
- Mitoxantrone Hydrochloride Liposome
- Catumaxomab
- Ipilimumab
- Relatlimab
- FLX475
- DP303c
- IDX-1197
- HLX22
- Olaparib
- LCAR-C18S
- ALX148
- KN026
- Atezolizumab
- Sintilimab
- QL1604
- NC410
- KH903
- GQ1001
- Amivantamab
- IMU-131
- BT8009
- VE800
- CPL304110
- ARX788
- MRG002
- SEA-TGT
Introduction
Executive Summary
Advanced Gastric Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Late Stage Products (Phase III)
Comparative Analysis
Camrelizumab: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Pamiparib: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
Venadaparib: Idience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Gastric Carcinoma Key Companies
Advanced Gastric Carcinoma Key Products
Advanced Gastric Carcinoma- Unmet Needs
Advanced Gastric Carcinoma- Market Drivers and Barriers
Advanced Gastric Carcinoma- Future Perspectives and Conclusion
Advanced Gastric Carcinoma Analyst Views
Advanced Gastric Carcinoma Key Companies
Appendix
Executive Summary
Advanced Gastric Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Late Stage Products (Phase III)
Comparative Analysis
Camrelizumab: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Pamiparib: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
Venadaparib: Idience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Gastric Carcinoma Key Companies
Advanced Gastric Carcinoma Key Products
Advanced Gastric Carcinoma- Unmet Needs
Advanced Gastric Carcinoma- Market Drivers and Barriers
Advanced Gastric Carcinoma- Future Perspectives and Conclusion
Advanced Gastric Carcinoma Analyst Views
Advanced Gastric Carcinoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Advanced Gastric Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Advanced Gastric Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Advanced Gastric Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Advanced Gastric Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products